Lovaza IIIts the only way for Lovaza to survive, period.
It would be rather foolish. AMRN does not know the final exclusivity of their product, and why would GSK get two similar products? Unless AMRN finds a strong marketing partner, they aren't going to be able to capitalize that well.
Because AMRN is superior to Lovaza. No doctor is going to prescribe Lovaza once AMRN hits the market.
No partner...buyer. Lovaza is useless and irrelevant if Pfizer gets a hold of it. Their reps and salesforce are second to none.